As a dual LXR/FXR receptor activator, withaferin A activates both LXR-α and FXR, inducing their canonical target genes (ABCA1 and ABCB11) and inhibiting diet-induced hepatic steatosis, steatohepatitis, and fibrosis [122]. Here, NR1H3 is linked to Hepatic steatosis.